

## *Curriculum Vitae*

**LUTZ NAEHRLICH** Prof. Dr. med.  
d.o.b. Apri, 18<sup>th</sup> 1966, in Frankfurt/Main, Germany

### **University Education**

2016 Habilitation Pediatric, Justus-Liebig University Giessen/Germany  
1994 Doctorate Medicine, Friedrich-Alexander-University Erlangen/Germany  
1987-1993 Studies of Medicine, Friedrich-Alexander-University Erlangen/Germany

### **Scientific Career**

Since 2020 Pharmacovigilance Study Director of the European Cystic Fibrosis Society Patient Registry  
2017-2020 Director of the European Cystic Fibrosis Society Patient Registry  
Since 2014 Medical Director of the German Cystic Fibrosis Registry  
Since 2013 Principal Investigator at Universities of Giessen and Marburg Lung Center (UGMLC)  
2012-2018 Lead of the Working Group Cystic Fibrosis, German Society of Pediatric Pulmonology  
Since 2001 Investigator of clinical studies in the field of Cystic fibrosis

### **Clinical Carrer**

Since 2010 Consultant at the Department of Pediatrics, Justus-Liebig University Giessen/Germany  
Since 2010 Head of Pediatric Cystic Fibrosis Center, Department of Pediatrics, University Hospital  
Giessen/Marburg, Giessen/Germany  
2007 Subspeciality in Pediatric Pulmonology  
2001-2010 Consultant at the Department of Pediatrics, Friedrich-Alexander-University  
Erlangen/Germany  
2000-2010 Head of the Pediatric Cystic Fibrosis Center, Friedrich-Alexander-University  
Erlangen/Germany  
1993-2001 Medical Residency, Department of Pediatrics, Friedrich-Alexander-University  
Erlangen/Germany

### **Citation Record**

Total citations: 6037, h-Index 39 (Google scholar 10th Mar 2026)

### **Top-10 selected Publications**

Sermet-Gaudelus I, Orenti A, Hatziagorou E, Bakkeheim E, **Naehrlich L**, Kerem E; ECFSPR Steering Group. Health inequity in people with cystic fibrosis: can we close the gap? *Ann Am Thorac Soc.* 2026 Feb 1;23(2):228-240. doi: 10.1513/AnnalsATS.202501-052OC.

Burgel PR, Orenti A, Cromwell E, Macek M, Gutierrez HH, Karadag B, Faro A, van Rens JG, **Naehrlich L**, Bakkeheim E, Carr SB, Lindblad A, Zolin A, Lammertyn E, Ruseckaite R, Zampoli M, Byrnes CA, da Silva-Filho L, Elbert A, Cheng SY, Stephenson AL; on the behalf of the ECFSPR scientific committee and the Global CF Registry Collaboration. Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor. *J Cyst Fibros.* 2025 Nov;24(6):1017-1026. doi: 10.1016/j.jcf.2025.10.007.

Halle O, Graeber SY, Kotsendorn J, Kessemeier C, Falke JN, Schwabe J, Schütz K, Pallenberg ST, Dalferth R, Grychtol R, Ringshausen FC, Stahl M, Thee S, Roehmel JF, Syunyaeva Z, Duerr J, Chung J, Hirtz S, Uselmann T, Kühbandner I, Rückes-Nilges C, Bagheri-Pothoff A, Barth S, Schaub B, Brinkmann F, Weber S, van Koningsbruggen-Rietschel S, Abdo M, Weckmann M, Widder S, Hansen G, Tümmler B, Sommerburg O, **Naehrlich L**, Mall MA, Dittrich AM.. Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis. *Eur Respir J*. 2025 Dec 4;66(6):2500150. doi: 10.1183/13993003.00150-2025.

Stahl M, Dohna M, Graeber SY, Sommerburg O, Renz DM, Pallenberg ST, Voskrebenezov A, Schütz K, Hansen G, Doellinger F, Steinke E, Thee S, Röhmel J, Barth S, Rückes-Nilges C, Berges J, Hämmerling S, Wielpütz MO, **Naehrlich L\***, Vogel-Claussen J\*, Tümmler B\*, Mall MA\*, Dittrich AM\*. Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Children with Cystic Fibrosis and One or Two *F508del* Alleles. *Eur Respir J*. 2024 Jul 26:2400004. doi: 10.1183/13993003.00004-2024.

Kerem E, Orenti A, Adamoli A, Hatziagorou E, **Naehrlich L**, Sermet-Gaudelus I, ECFS Patient Registry Steering Group. Cystic fibrosis in Europe: improved lung function & longevity: reasons for cautious optimism, but challenges remain. *European Respiratory Journal*; 2024 Mar 7;63(3):2301241. DOI: 10.1183/13993003.01241-2023

Sutharsan S #, Dillenhoefer S #, Welsner M, Stehling F, Brinkmann F, Burkhart M, Ellemunter H, Dittrich AM, Smaczny C, Eickmeier O, Kappler, Schwarz C, Sieber S, Naehrig S, **Naehrlich L**, on behalf of the German CF Registry of the Mukoviszidose e.V. and participating CF sites. *Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry*. *The Lancet Regional Health - Europe* 2023 , Sep 2023; 32: 2-11. <https://doi.org/10.1016/j.lanepe.2023.100690>

Dittrich AM, Sieber S, **Naehrlich L**, Burkhart M, Hafkemeyer S, Tümmler B; Registry Working Group of the German CF Registry. Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of *Staphylococcus aureus* and *Pseudomonas aeruginosa* dependent on age and lung function in people with cystic fibrosis. *Int J Infect Dis*. 2023 Nov 28:139:124-131. doi: 10.1016/j.ijid.2023.11.013.

McKone, E, Ariti, C, Jackson, A, Zolin, A, Carr, SB, Orenti, A, Van Rens, J, Lemonnier, L, Macek, M, Keogh RH, **Naehrlich L**, European Cystic Fibrosis Society Patient Registry. Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study. *Eur Respir J* 2021 Oct 1;58(3):2002288.

**Naehrlich L**, Orenti A, Dunlevy F, Kasmi I, Harutyunyan S, Pflieger A, Keegan S, Daneau G, Petrova G, Tješić-Drinković D, Yiallourous P, Bilkova A, Olesen HV, Burgel P-R, Parulava T, Diamantea F, Párniczky A, McKone EF, Mei-Zahav M, Salvatore M, Colombo C, Aleksejeva E, Malakauskas K, Schlessner M, Fustik S, Turcu O, Zomer-van Ommen D, Wathne AS, Woźniacki L, Pereira L, Pop L, Kashirskaya N, Rodić M, Kayserova H, Krivecs U, Mondejar-Lopez P, de Monestrol I, Dogru D, Makukh H, Cosgriff R, van Koningsbruggen-Rietschel S, Jung A, European Cystic Fibrosis COVID project group. *Incidence of SARS-*

*CoV-2 in people with cystic fibrosis in Europe between February and June 2020.* J Cyst Fibros 2021 Jul;20(4):566-577. Doi: 10.1016/j.jcf.2021.03.017

Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, Régis P-R Burgel, Tullis E, Castaños C, Castellani C, Byrnes CA, Cathcart F, Chotirmall SH, Cosgriff R, Eichler I, Fajac I, Goss CH, Drevinek P, Farrell PM, Gravelle AM, Havermans T, Mayer-Hamblett N, Kashirskaya N, Kerem E, Mathew JL, McKone EF, **Naehrlich L**, Nasr SZ, Oates GR, O'Neill C, Pypops U, Raraigh KS, Rowe SM, Southern KW, Sivam S, Stephenson AL, Zampoli M, Ratjen F. The future of cystic fibrosis care: a global perspective. Lancet Resp Med 2020 Jan;8(1):65-124. Doi: 10.1016/S2213-2600(19)30337-6